Claudin5 protects the peripheral endothelial barrier in an organ and vessel type-specific manner
- Uppsala University, Sweden
- University of Oulu, Finland
Abstract
Dysfunctional and leaky blood vessels resulting from disruption of the endothelial cell (EC) barrier accompanies numerous diseases. The EC barrier is established through endothelial cell tight and adherens junctions. However, the expression patterning and precise contribution of different junctional proteins to the EC barrier is poorly understood. Here, we focus on organs with continuous endothelium to identify structural and functional in vivo characteristics of the EC barrier. Assembly of multiple single-cell RNAseq datasets into a single integrated database revealed the variability and commonalities of EC barrier patterning. Across tissues, Claudin5 exhibited diminishing expression along the arteriovenous axis, correlating with EC barrier integrity. Functional analysis identified tissue-specific differences in leakage patterning and response to the leakage agonist histamine. Loss of Claudin5 enhanced histamine-induced leakage in an organotypic and vessel type-specific manner in an inducible, EC-specific, knock-out mouse. Mechanistically, Claudin5 loss left junction ultrastructure unaffected but altered its composition, with concomitant loss of zonula occludens-1 and upregulation of VE-Cadherin expression. These findings uncover the organ-specific organisation of the EC barrier and distinct importance of Claudin5 in different vascular beds, providing insights to modify EC barrier stability in a targeted, organ-specific manner.
Data availability
The murine ear skin data has been deposited in GEO under accession number GSE202290. Further details regarding specifics of the analysis will be available upon reasonable request.
-
Claudin5 protects the peripheral endothelial barrier in an organ and vessel type-specific mannerNCBI Gene Expression Omnibus, GSE202290.
-
A single-cell transcriptomic atlas characterizes ageing tissues in the mouseGene Expression Omnibus, GSE132042.
Article and author information
Author details
Katarzyna Koltowska
Lena Claesson-Welsh
Funding
Vetenskapsrådet (2020-01349)
- Lena Claesson-Welsh
Åke Wiberg Stiftelse (M21-0109)
- Sofia Nordling
Svenska Sällskapet för Medicinsk Forskning
- Elin Sjöberg
Svenska Sällskapet för Medicinsk Forskning (201912)
- Mark Richards
European Molecular Biology Organization (ALTF 923-2016)
- Mark Richards
Knut och Alice Wallenbergs Stiftelse (2020.0057)
- Lena Claesson-Welsh
Knut och Alice Wallenbergs Stiftelse (2019.0276)
- Lena Claesson-Welsh
Fondation Leducq (17 CVD 03)
- Lena Claesson-Welsh
Cancerfonden (19 0119 Pj)
- Lena Claesson-Welsh
Cancerfonden (19 0118 Us)
- Lena Claesson-Welsh
Cancerfonden (20 1086 Pj)
- Marleen Gloger
- Katarzyna Koltowska
Knut och Alice Wallenbergs Stiftelse (2017.0144)
- Katarzyna Koltowska
Ragnar Söderbergs stiftelse (M13/17)
- Katarzyna Koltowska
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: In vivo animal experiments were carried out in accordance with the ethical permit provided by the Committee on the Ethics of Animal Experiments of the University of Uppsala (permit 6789/18).
Copyright
© 2022, Richards et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Claudin5 protects the peripheral endothelial barrier in an organ and vessel type-specific manner
eLife 11:e78517.
https://doi.org/10.7554/eLife.78517
Further reading
-
- Cell Biology
Centrioles have a unique, conserved architecture formed by three linked, ‘triplet’, microtubules arranged in ninefold symmetry. The mechanisms by which these triplet microtubules are formed remain unclear but likely involve the noncanonical tubulins delta-tubulin and epsilon-tubulin. Previously, we found that human cells lacking delta-tubulin or epsilon-tubulin form abnormal centrioles, characterized by an absence of triplet microtubules, lack of central core protein POC5, and a futile cycle of centriole formation and disintegration (Wang et al., 2017). Here, we show that human cells lacking either TEDC1 or TEDC2 have similar abnormalities. Using ultrastructure expansion microscopy, we observed that mutant centrioles elongate to the same length as control centrioles in G2 phase and fail to recruit central core scaffold proteins. Remarkably, mutant centrioles also have an expanded proximal region. During mitosis, these mutant centrioles further elongate before fragmenting and disintegrating. All four proteins physically interact and TEDC1 and TEDC2 can form a subcomplex in the absence of the tubulins, supporting an AlphaFold Multimer model of the tetramer. TEDC1 and TEDC2 localize to centrosomes and are mutually dependent on each other and on delta-tubulin and epsilon-tubulin for localization. Our results demonstrate that delta-tubulin, epsilon-tubulin, TEDC1, and TEDC2 function together to promote robust centriole architecture, laying the foundation for future studies on the mechanisms underlying the assembly of triplet microtubules and their interactions with centriole structure.
-
- Cancer Biology
- Cell Biology
The most common primary malignancy of the liver, hepatocellular carcinoma (HCC), is a heterogeneous tumor entity with high metastatic potential and complex pathophysiology. Increasing evidence suggests that tissue mechanics plays a critical role in tumor onset and progression. Here, we show that plectin, a major cytoskeletal crosslinker protein, plays a crucial role in mechanical homeostasis and mechanosensitive oncogenic signaling that drives hepatocarcinogenesis. Our expression analyses revealed elevated plectin levels in liver tumors, which correlated with poor prognosis for HCC patients. Using autochthonous and orthotopic mouse models we demonstrated that genetic and pharmacological inactivation of plectin potently suppressed the initiation and growth of HCC. Moreover, plectin targeting potently inhibited the invasion potential of human HCC cells and reduced their metastatic outgrowth in the lung. Proteomic and phosphoproteomic profiling linked plectin-dependent disruption of cytoskeletal networks to attenuation of oncogenic FAK, MAPK/Erk, and PI3K/Akt signatures. Importantly, by combining cell line-based and murine HCC models, we show that plectin inhibitor plecstatin-1 (PST) is well-tolerated and potently inhibits HCC progression. In conclusion, our study demonstrates that plectin-controlled cytoarchitecture is a key determinant of HCC development and suggests that pharmacologically induced disruption of mechanical homeostasis may represent a new therapeutic strategy for HCC treatment.
